The cardiotoxic effects of CAR‐T cell therapy: An updated systematic review and meta‐analysis
- 22 August 2024
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 113 (6) , 798-809
Abstract
Background: Chimeric antigen receptor T‐cell (CAR‐T) therapy has shown promise in treating hematologic malignancies, yet its potential cardiotoxic effects require thorough investigation.Objectives: We aim to conduct a systematic review and meta‐analysis to examine the cardiotoxic effects of CAR‐T therapy in adults with hematologic malignancies.Methods: We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for studies reporting cardiovascular outcomes, such as arrhythmias, heart failure, and reduced left ventricle ejection fraction (LVEF).Results: Our analysis of 20 studies involving 4789 patients revealed a 19.68% incidence rate of cardiovascular events, with arrhythmias (7.70%), heart failure (5.73%), and reduced LVEF (3.86%) being the most prevalent. Troponin elevation was observed in 23.61% of patients, while NT‐Pro‐BNP elevation was observed in 9.4. Subgroup analysis showed higher risks in patients with pre‐existing conditions, such as atrial arrhythmia (OR 3.12; p < .001), hypertension (OR 1.85; p = .002), previous heart failure (OR 3.38; p = .003), and coronary artery disease (OR 2.80; p = .003).Conclusion: Vigilant cardiovascular monitoring is crucial for patients undergoing CAR‐T therapy to enhance safety and treatment efficacy.Novelty Statements.Keywords
This publication has 31 references indexed in Scilit:
- Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-AnalysisTransplantation and Cellular Therapy, 2024
- Incidence of MACE in Patients Treated With CAR-T Cell TherapyJACC: Cardiooncology, 2023
- Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell TherapyJACC, 2021
- Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System AnalysisTransplantation and Cellular Therapy, 2020
- Cardiovascular Effects of CAR T Cell TherapyJACC: Cardiooncology, 2020
- CAR T Cell Therapy–Related Cardiovascular Outcomes and ManagementJACC: Cardiooncology, 2020
- Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)JACC, 2019
- Capillary leak syndrome: etiologies, pathophysiology, and managementKidney International, 2017
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaMolecular Therapy, 2017
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialThe Lancet, 2015